Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $16 million, representing a 4% decline year-over-year primarily due to lower system sales [19] - Full year 2025 revenue increased by 9% compared to 2024, with recurring revenue growing by 15% [21][22] - Gross margin for Q4 2025 was $6.9 million, representing a gross margin percentage of 43%, compared to 42% in Q4 2024 [23] - Full year gross margin was 46%, down from 48% in 2024, attributed to inflationary cost increases and tariffs [24] Business Line Data and Key Metrics Changes - The installed base of ALLY systems grew to approximately 200, up 48% year-over-year, with procedure volume increasing by 20% year-over-year in Q4 2025 [23] - Procedure volumes for the full year 2025 surpassed 206,000 globally, reflecting a 22% growth [23] - U.S. ALLY sales in Q4 2025 included 12 systems, an increase of 1 system from Q4 2024, while international sales dropped significantly [19][20] Market Data and Key Metrics Changes - Market share in the U.S. increased from 14% to 23.4% over 3.5 years, with significant gains from replacing first-generation lasers [10] - The company noted that nearly 50% of new systems in Q4 2025 were sold to femto-naive surgeons, expanding the market for laser-assisted cataract surgery [11] Company Strategy and Development Direction - The company aims to focus on growing procedure volumes and recurring revenue through additional system placements and increased utilization of existing systems [16] - Plans to re-engage with distributors and key stakeholders to regain momentum in international markets following the termination of the acquisition [15] - The company is exploring new market opportunities, including Australia and New Zealand, and intends to expand its presence in Europe and Southeast Asia [52][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to historical operating performance and emphasized the importance of rebuilding momentum over the next several quarters [9][26] - The termination of the merger was viewed as an opportunity to focus on independent growth and capitalize on market opportunities [66] - Management acknowledged the challenges faced during the acquisition process but highlighted the potential for long-term success and value creation [15][66] Other Important Information - The company received a $10 million transaction deposit following the termination of the merger, which will enhance cash flow [8][18] - Adjusted EBITDA for Q4 2025 was positive at $595,000, indicating operational cash flow positivity despite the challenges faced [25] Q&A Session Summary Question: Distributor commentary and growth re-acceleration - Management noted that while initial conversations with distributors have been positive, it will take several quarters to regain momentum in international markets due to previous uncertainties [30][33] Question: U.S. procedure growth and recurring revenue - Management indicated that U.S. procedure growth remains strong, with expectations for continued growth in recurring revenue as the installed base of systems increases [41][43] Question: Operating expenses and future projections - Management confirmed that cash-based operating expenses are expected to increase by no more than 10% in 2026, primarily focused on commercial activities [37][49]

Financial Data and Key Metrics Changes - For the year ended December 31, 2025, total revenue was approximately $54 million, down 18% from approximately $66 million in 2024, primarily due to lower contributions from healthcare operations [18] - Healthcare operations revenue was approximately $40 million in 2025, compared to approximately $52 million in 2024, with Q4 revenue of approximately $9 million stable compared to $10 million in Q3 [19] - Consolidated gross margin for the full year was approximately 20%, down from approximately 26% in 2024, but showed sequential improvement late in Q4 [21][22] Business Line Data and Key Metrics Changes - The healthcare segment represented about 73% of total revenue in 2025, generating nearly $40 million in sales, all from Florida [9] - A 94% increase in 340B contract revenue was reported in Q4 2025 compared to Q3 2025, driven by new business development and higher margin services [8][19] - E-commerce operations revenue increased to approximately $15 million, up 6% year-over-year, supported by strong demand for satellite connectivity and IoT products [20] Market Data and Key Metrics Changes - The healthcare segment is expanding from Florida to nationwide operations, leveraging a partnership with HealthWarehouse to support customers in all 50 states [4][9] - The e-commerce segment continues to grow, with new sales records set for IoT hardware and recurring high-margin airtime revenue [10] Company Strategy and Development Direction - The company is focused on improving operations, reducing costs, and driving profitability, with a strategic shift towards higher margin, recurring revenue streams [3][25] - The management team emphasizes the importance of maintaining Nasdaq listing as part of growth and expansion plans, which necessitated a reverse stock split [3][28] - The company aims to leverage its partnership with HealthWarehouse to create new revenue streams and expand its healthcare offerings nationally [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about early signs of margin improvement and reduced operating losses expected in the latter half of 2026 [7][25] - The company anticipates continued growth in 340B contract revenue and fulfillment services, with gradual improvement in prescription volumes [20][26] - Management highlighted the importance of cost optimization and strategic refocusing initiatives that are beginning to materialize in financial performance [18][25] Other Important Information - The company reported a significant reduction in operating expenses by approximately 25% to $20 million in 2025, compared to $26 million in 2024 [22] - The company ended the year with nearly $14 million in cash and no meaningful debt, providing flexibility for operations and growth investments [23] Q&A Session Summary Question: Was the reverse split necessary? - Management stated that the reverse split was necessary to maintain Nasdaq listing, as the buyback program expired and was not a viable option [27][28] Question: What are the current plans for the buyback? - Management is considering reinstating the buyback program and will announce details when appropriate [29] Question: What is the status of ongoing lawsuits? - Management is working with counsel to resolve remaining legal matters, with options to proceed to trial or reach a settlement [30]

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $12.5 million, roughly even compared to the previous year, with gross profit of $3.4 million and a gross margin of 27%, up from 22% in Q4 2024 [4][5] - Full year 2025 revenue reached a record $62.1 million, up 18.6% from $51.9 million in 2024, while full year gross profit was $16.1 million, slightly down from $16.2 million in 2024 [5][6] - Adjusted EBITDA for 2025 was $4.2 million, less than 7% of revenue, with a target to improve EBITDA to double digits in 2026 [6][7] Business Line Data and Key Metrics Changes - The company launched 20 new brand partners in 2025, contributing to substantial revenue growth [5] - Transition costs and operational inefficiencies from facility consolidation impacted margins, with labor costs and inventory control being significant challenges [6][10] Market Data and Key Metrics Changes - The company anticipates a normalization period in revenue, with current open orders at just under $33 million compared to $38 million a year ago [9] - The beauty sector remains resilient, with consumers viewing beauty as an affordable luxury, particularly in SPF-infused skincare [16] Company Strategy and Development Direction - The "Transform and Transcend" initiative aims to enhance operational health and profitability, focusing on operational excellence, technology-driven expansion, product development, and collaborative globalization [12][14] - The company plans to establish a 30% gross margin floor as a target for 2026 and aims to increase free cash flow by improving procurement operations [7][8] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenges in operational execution due to rapid growth and emphasizes the need for improved efficiency to achieve sustainable profitability [11][17] - The company is optimistic about future growth, targeting a return to growth rates that exceed industry averages, driven by innovation and strategic partnerships [28][30] Other Important Information - The company increased its patent portfolio by 20%, now totaling over 120 patents, which strengthens its market position [10] - The new product, DayMode Hero Concealer, has received recognition in multiple categories, indicating strong market potential [10] Q&A Session Summary Question: Will EPS in 2026 be at or above 2024 levels? - Management is not prepared to provide EPS guidance but expects EBITDA to return to double digits in 2026 [20][21] Question: What is the roadmap to grow the company to $200 million? - The company is focused on addressing operational challenges and leveraging its innovation platform to resume growth at multiples of the industry's growth rate [27][29] Question: Are there plans for a dedicated investor call? - Management intends to improve communications and provide further information in the future [35] Question: Why has production struggled? - The company faced challenges due to simultaneous growth and the installation of new capabilities, impacting gross profit margins [36][37] Question: Did the company lose a brand partner? - Management clarified that there was no loss of a brand partner, but challenges were noted with sell-through from one of the mass-market customers [38] Question: Why did it take so long to schedule the call? - The call was scheduled post-year-end audit completion, which is planned almost a year in advance [39] Question: Will there be an improvement in sales this year? - Management anticipates a normalization period for sales but remains optimistic about future growth due to new leadership and partnerships [40][41]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 increased approximately 9% year-over-year to $140.7 million, driven primarily by wholesale growth [4][19] - Full-year 2025 net revenue was $468.7 million, reflecting a 3.9% decline compared to the prior year [22] - Adjusted EBITDA for Q4 was approximately $8.8 million, a significant improvement from $2.9 million in the previous year [4][22] - Full-year adjusted EBITDA was $1.9 million, compared to an adjusted EBITDA loss of $20.8 million in 2024 [25] - Gross margin for Q4 was approximately 41.9%, down 100 basis points from last year but well above the 40% target [20][22] Business Line Data and Key Metrics Changes - Direct-to-consumer (DTC) net revenue for Q4 was $71.9 million, down 9.9% year-over-year, with showroom revenue increasing approximately 4.5% [19][22] - Wholesale revenue increased approximately 39.8% in Q4, driven by expanded partnerships with Mattress Firm and Costco [19][22] - E-commerce revenue declined by 15.3% in Q4, reflecting mixed performance throughout the year [19][22] Market Data and Key Metrics Changes - Comparable sales in showrooms increased 8.8% in Q4, with over 80% of showrooms being four-wall profitable for the full year [6][19] - The overall market remains challenging, with the broader market down low single digits [4][6] Company Strategy and Development Direction - The company is focused on three priorities: deepening consumer understanding, enhancing product experience, and executing with financial discipline [8][12] - The launch of the Purple Royale collection is a significant step in the premium strategy, complementing the Rejuvenate 2.0 collection [11][12] - The company aims to expand its distribution presence, particularly through partnerships with Mattress Firm and Costco, which have exceeded initial expectations [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with improved stability and a structurally stronger operating model, expecting revenue between $500 million and $520 million [16][27] - The company anticipates adjusted EBITDA of $20 million to $30 million for 2026, driven by operational efficiencies and ongoing restructuring actions [16][27] - Management acknowledged ongoing strategic alternatives review to maximize shareholder value, including potential mergers or sales [17][28] Other Important Information - The company ended Q4 with cash and cash equivalents of $24.3 million, down from $29 million a year prior, but extended debt maturities to April 2027 [25][26] - The company achieved profitability levels not seen since 2021, driven by structural changes and cost management initiatives [28][30] Q&A Session Summary Question: Recent trends and Q1 outlook - Management noted a strong Q4 but indicated that January showed a step back due to inventory dynamics and expected Q1 to be historically weak [33][34] Question: Flow-through margin expectations - Management expects a healthy flow-through margin, with guidance indicating a revenue increase of $30 million to $50 million and improved EBITDA [36][37] Question: Exposure to raw material price pressures - Management acknowledged mixed exposure to petrochemical prices but indicated that tariff savings could offset potential increases [38][40] Question: Seasonality and revenue growth expectations - Management expects consistent revenue growth throughout the year, with a boost from the Purple Royale launch in Q2 [45][49] Question: Drivers of flow-through and restructuring actions - Management confirmed that actions taken previously will benefit operating expenses and gross margins, with no additional actions planned [50][51] Question: Demand trends from retail partners - Management reported mixed growth across wholesale partners, with some performing well while others lagged [61] Question: Cash flow expectations for 2026 - Management anticipates positive free cash flow for 2026, supported by improved EBITDA profitability [63][64] Question: Showroom channel performance - Management highlighted strong comp growth in showrooms, attributing it to positive product mix and operational discipline [65][66]

Financial Data and Key Metrics Changes - Prairie generated approximately $242 million in revenue for 2025, or $315 million including Bayswater, reflecting a nearly 3,000% increase in revenues year-over-year [9][10] - Adjusted EBITDA totaled approximately $156 million, a significant improvement from the prior year, with full-year adjusted EBITDA expected to be around $220 million when including Bayswater [10][12] - The net loss attributable to common stockholders was $60.9 million, or $1.35 per share, primarily due to non-cash expenses [9] Business Line Data and Key Metrics Changes - Total production for the year was approximately 6.75 million BOE, averaging 18,500 BOE per day, with an exit rate of approximately 28,000 net BOE per day [4][5] - Including Bayswater's pro forma production, full-year production would have been approximately 24,000 BOE per day, representing almost a 4x increase year-over-year [5] Market Data and Key Metrics Changes - Realized prices were $63.87 per barrel of oil, $17.93 per barrel of NGL, and $1.65 per Mcf of natural gas [9] - Prairie ended the year with 121.1 million BOE of proved reserves, with a PV-10 value of approximately $1.2 billion [12] Company Strategy and Development Direction - The company remains focused on disciplined capital allocation, operational execution, and delivering sustainable growth and long-term shareholder value [6][14] - Prairie plans to maintain a capital expenditure range of $200 million to $220 million for 2026, with expected average production of approximately 25,500 to 27,500 BOE per day [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial success moving into 2026, highlighting the strength of the asset base and the momentum exiting 2025 [15][16] - The leadership team is committed to enhancing financial strength and operational excellence while maintaining flexibility for accretive opportunities [14][15] Other Important Information - Prairie executed a series of bolt-on acquisitions throughout 2025, adding approximately 44,000 net acres and expanding its portfolio with high-quality proved inventory [5][12] - The company achieved a 0.0 safety record for the year, reflecting a perfect safety performance with zero incidents [12] Q&A Session Summary Question: Production guidance and cadence throughout the year - Management indicated that Q1 production is expected to average around 23,000 BOE per day due to shut-in production, with a gradual increase anticipated throughout the year [20][21] Question: Well performance and recent declines - Management noted that Opal Coal Bank wells performed above expectations, while Noble and Simpson wells faced challenges due to offset operators and equipment delays [22][25] Question: Current share count and preferred refinancing - The share count has increased from the low sixties at year-end, with ongoing conversions from preferred shares [28] Question: Cash flow priorities for 2026 - Management plans to use free cash flow for debt reduction and potential acquisitions, maintaining a conservative approach to capital allocation [31][33] Question: Anticipated constraints from midstream systems - Management does not foresee any constraints on production plans through 2026 or 2027, having aligned development plans with midstream partners [35][36] Question: Flexibility around CapEx guidance - Management emphasized the goal of bolstering the balance sheet and generating free cash flow, with a focus on operational efficiencies [38][42] Question: Changes in strategy post-management transition - Management confirmed that there would be no changes in operations or strategy following the transition, maintaining alignment and focus [54]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $32.4 million, a 3% increase from $31.5 million in Q4 2024, despite a $2 million revenue loss due to the early closure of the Companion Spine transaction [4][12] - Full year 2025 revenue reached $133.9 million, representing a 14% growth from $117.3 million in 2024 [6][16] - Adjusted EBITDA for Q4 2025 was $1.9 million, compared to approximately $0.4 million in Q4 2024, while full year adjusted EBITDA was $16.3 million, a significant improvement from a loss of $2.3 million in 2024 [19][16] - Net income for Q4 2025 was $57,000, compared to a net loss of $3.2 million in Q4 2024, and full year net income was $5 million, compared to a net loss of $16.5 million in 2024 [16][19] Business Line Data and Key Metrics Changes - The biologics product family was essentially flat in Q4 2025, but is expected to grow due to new product launches and increased sales force [6][8] - The sale of non-core assets to Companion Spine was transformational, allowing the company to focus on high-margin biologics [5][11] - Gross margin for Q4 2025 was 54.9%, up from 50.8% in Q4 2024, driven by a favorable sales mix [14] Market Data and Key Metrics Changes - The company anticipates organic growth in its core biologics business, despite headwinds from the divestiture and loss of license revenue [11][12] - The hardware business is expected to decline at a steady rate, approaching high teens percentage in 2026 [30] Company Strategy and Development Direction - The company is focused on self-sustainability, positive cash flows, and tighter operating discipline, with a strategic emphasis on in-house manufacturing [7][11] - Plans to double the number of regional sales representatives and expand the national accounts team to drive institutional adoption [8][11] - Continued investment in R&D and new product introductions is central to the company's growth strategy [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and foundation for growth, with a revenue outlook for 2026 projected between $95 million and $99 million [11][12] - The company expects to maintain positive free cash flow and does not anticipate the need for additional outside capital [5][11] Other Important Information - The company completed the sale of its Coflex assets for approximately $21.4 million, which has strengthened its cash position [5][6] - Cash equivalents and restricted cash as of December 31, 2025, were $17.3 million, up from $6.2 million in 2024 [20] Q&A Session Summary Question: Outlook for 2026 and organic growth in core biologics business - Management expects sequential quarter-over-quarter growth in 2026, driven by new product offerings and an expanded commercial organization [24] Question: Headwinds from loss of license revenue related to Q-Codes - The Q-Code revenue will cease, but management anticipates ramping up sales under the Xtant brand as distributors shift to using their contracts [26] Question: Decline in hardware business throughout 2026 - A slow decline in the hardware business is expected, with a steady rate approaching high teens percentage [30] Question: Specific products expected to support biologics growth - Key products include OsteoVive Plus, OsteoFactor Pro, and CollagenX, with significant growth opportunities identified [34] Question: Growth channels for biologics business - The majority of growth is expected to come from Xtant branded products through independent agent networks, with OEM channels contributing around 20% [38][42] Question: Strategic thoughts on the hardware business - The hardware business is still beneficial for the biologics segment, but management is evaluating its long-term strategic value [45]

Financial Data and Key Metrics Changes - For the full year 2025, revenues reached $427 million, representing a 142% year-over-year increase from the prior year [13] - Gross profit increased by 340% to $96.3 million in 2025, up from $21.9 million in 2024, with gross profit margin expanding to 22.5% from 12.4% in 2024 [13][14] - EBITDA was $95.8 million in 2025, a 40% increase from $68.2 million in the prior year, while non-GAAP adjusted EBITDA was $110.8 million, up by 228% compared to $33.8 million in the previous year [15][16] - GAAP net income was $37.2 million for 2025, compared to $40.5 million for the same period last year, while adjusted net income was $52.2 million, compared to $6 million in 2024 [16][17] - Cash flow from operations was $133 million, with $58.9 million in cash and restricted cash as of December 31, 2025, compared to $17.2 million as of December 31, 2024 [18] Business Line Data and Key Metrics Changes - The primary growth driver was a $241 million increase in solar cell sales, with 2.3 gigawatts shipped from Ethiopia to U.S. customers and 1.9 gigawatts from Vietnam to international markets [5][13] - The company launched a new 1 gigawatt module facility in Houston in Q4 2025, delivering 249 megawatts of modules [6][7] Market Data and Key Metrics Changes - The company is positioned to meet the accelerating demand in the U.S. solar market, with shipment guidance for 2026 set between 5.5 and 5.8 gigawatts for solar cells and 1 to 1.3 gigawatts for solar modules [10][11] - The operational focus for 2026 includes maximizing existing infrastructure and expanding U.S. module capacity to 2 gigawatts [11][12] Company Strategy and Development Direction - The company aims to strengthen its position as a vertically integrated solution provider, focusing on high-demand and compliant manufacturing hubs [5] - The acquisition of the BridgeSun brand is intended to streamline operations and enhance growth without diluting shareholder value [7][9] - Plans for 2026 include significant investments in R&D and technology to establish a robust technology leadership position within the U.S. [12] Management's Comments on Operating Environment and Future Outlook - Management highlighted the challenges faced in the solar industry but emphasized the successful doubling of revenue and increased gross margins as validation of the company's strategy [10] - The company anticipates a favorable domestic policy environment that prioritizes high-efficiency, traceable technology [11] Other Important Information - The company plans to report quarterly earnings starting from 2026, enhancing engagement with the investor community [28] Q&A Session Summary Question: Insights on gross margins with increased U.S. revenue share - Management indicated that they are not currently providing specific gross margin guidance but expect to maintain competitive margins as operations ramp up [21][22] Question: Potential credits for Houston production capacity - Management is cautious about providing guidance for Houston production but aims for 60%-70% utilization of the current 1 gigawatt capacity, with pilot production for an additional 1 gigawatt expected in Q3 or Q4 [26][27] Question: Future earnings call frequency - Management confirmed plans to report quarterly earnings starting this year, with the first quarter numbers expected in May [28]

2026 Investor Day March 31, 2026 SUNCOR ENERGY 1 Agenda 1 Today's Suncor 5 Why buy Suncor SUNCOR ENERGY 2 Rich Kruger Chief Executive Officer Troy Little Chief Financial Officer Peter Zebedee Executive VP, Upstream Dave Oldreive Executive VP, Downstream 2 We're not done yet 3 Superior returns 4 Oil sands future Shelley Powell Senior VP, Operations Improvement & Support Services Adam Albeldawi Senior VP, External Affairs & Chief HR Officer Executive summary Today's Suncor … rebuilt to win • Comprehensive int ...

Financial Data and Key Metrics Changes - In 2025, AlTi generated $255 million in total revenues, representing a 29% growth compared to 2024, driven by robust AUM expansion and contributions from alternative interests [12][15] - Total assets under management reached $50 billion at year-end, up 10% year-over-year, despite foreign exchange headwinds impacting international business [15] - Adjusted EBITDA increased 45% to approximately $35 million for the year, with adjusted EBITDA margins at 14% [19] Business Line Data and Key Metrics Changes - The core revenue base remained anchored in nearly $200 million of predictable recurring management fees, which increased by 9% year-over-year [12][17] - The endowment and foundation business grew to more than $8 billion in assets under management, reflecting strong demand from private and family foundations [9] Market Data and Key Metrics Changes - The company experienced strong investment performance, particularly in its merger arbitrage strategy, which generated an 11.3% return for the year [16][40] - The growth in AUA was significantly influenced by the acquisition of Kontora, a German multi-family office, which contributed to increased revenue and AUA [41] Company Strategy and Development Direction - AlTi aims to build a premier global wealth management platform focused on the ultra-high net worth segment, with a commitment to delivering holistic and independent wealth management solutions [4][8] - The company has exited its non-core International Real Estate business to streamline operations and reduce costs, adopting a zero-based budgeting approach to identify recurring annual savings of approximately $20 million [11][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained growth and increased profitability, emphasizing the importance of a simplified operating model and durable client relationships [21][22] - The strategic review committee continues to evaluate options to maximize long-term shareholder value, with no proposals received to date that encapsulate the business's long-term value [13] Other Important Information - The company has maintained industry-leading client retention rates above 95% since its listing [4] - A transition in leadership was announced, with Nancy Curtin stepping in as Interim CEO following Michael Tiedemann's departure after 25 years [5][8] Q&A Session Summary Question: Can you provide more color on the decision to transition CEOs? - The transition was a thoughtful decision by the board and management, aimed at positioning AlTi for its next growth chapter while maintaining the existing strategy [25][27] Question: Can you discuss the focus on operating and how it fits together? - The strategy remains focused on being a preeminent global leader in the ultra-high net worth market, with an emphasis on organic growth and cost optimization through zero-based budgeting [30][32] Question: Can you elaborate on the merger arbitrage performance? - The merger arbitrage strategy had a strong year with performance up over 11%, contributing to improved management fees and incentive fees [38][39] Question: What is the status of the Allianz 13D filing? - Allianz has been a strategic partner for 18 months, and while their intentions are unclear, any proposals would go through the special committee of independent directors [45][47] Question: What is the current status of zero-based budgeting? - Zero-based budgeting has identified $20 million in potential savings, with improvements expected as contracts expire over the next several quarters [49][51] Question: What is the company's position on capital for growth and acquisitions? - The company does not currently need funding for organic growth but is confident in its ability to raise capital for attractive M&A opportunities if they arise [54][56]

Financial Data and Key Metrics Changes - For the full year 2025, AirJoule Technologies reported net operating expenses of $13.6 million, an increase from $11.2 million in 2024, primarily due to a $4.2 million rise in non-cash stock-based compensation [28] - The net loss for the full year was $9 million, with a significant loss from investment in the AirJoule joint venture amounting to $39.3 million, compared to $5.3 million in 2024 [28][29] - The company ended 2025 with approximately $22 million in cash, and after a January 2026 equity offering, the combined cash position was approximately $44 million with no debt [30][31] Business Line Data and Key Metrics Changes - The company focused on technology validation and product development, transitioning from laboratory demonstrations to real-world field deployments, with systems operating in Texas, Arizona, California, and Dubai [6][9] - The AirJoule Core product, optimized for industrial dehumidification and water generation, is expected to be commercially available in late Q4 2026 [19][25] - The larger AirJoule Prime system is currently being built and will serve as a showcase for industrial-scale water generation [20][25] Market Data and Key Metrics Changes - The Middle East is highlighted as a critical market due to its water stress, with Gulf nations relying on desalination for 70%-90% of their drinking water [15] - The ongoing geopolitical conflicts have exposed vulnerabilities in centralized water infrastructure, increasing the urgency for distributed water generation solutions like those offered by AirJoule [5][16] Company Strategy and Development Direction - The company aims to build a commercial pipeline in 2026, focusing on securing long-term customer commitments across various sectors, including data centers, industrial, defense, and international markets [13][14] - AirJoule's strategy emphasizes distributed water generation, which operates independently of traditional water supply systems, addressing the urgent need for water resilience [6][16] Management's Comments on Operating Environment and Future Outlook - Management noted the growing urgency of water resilience due to environmental and geopolitical factors, which has accelerated interest in AirJoule's technology [4][8] - The company expects 2026 to be a pivotal year for transitioning to commercial pipeline building, with a focus on establishing customer relationships that will support scaled commercial activity in 2027 and beyond [13][26] Other Important Information - The company completed a $15 million private placement and a $23 million equity offering in January 2026, ensuring sufficient capitalization for commercialization efforts [12][31] - AirJoule has established partnerships with GE Vernova and TenX Investment to enhance its market presence and accelerate commercialization [11][14] Q&A Session Summary Question: Customer engagement strategies - The company engages customers through direct outreach, warm introductions, and participation in conferences, with a focus on addressing urgent water needs in sectors like data centers [35][38] Question: Supply chain concerns - Most components are commercially available, with the only custom part being the aluminum vacuum chamber, which is produced at scale [39][40] Question: Capital expenditure needs for 2026 - The anticipated capital calls for the joint venture are part of the normal funding plan, with no major additional CapEx expected for 2026 [42][44] Question: Expected gross margins - Initial gross margins are less emphasized, with long-term targets of 30%-35% as the company transitions to contract manufacturing [49][50] Question: Competing with desalination - AirJoule's value proposition lies in speed to market and water quality, despite desalination being cheaper in operating costs [53][54] Question: Commercial opportunities and deployments - The company is engaging in various verticals, including residential, data centers, and military, with expectations for proof of value deployments leading to commercial commitments [61][66]